Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

Giorgio Bedogni, Stefano Bellentani, L. Miglioli et al. · BMC Gastroenterology · 2006 · 2.9K citations · Full text

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

Gregory Gaich, Jenny Y. Chien, Haoda Fu et al. · Cell Metabolism · 2013 · 867 citations · Full text

Obesity, Metabolic Syndrome, Health Sciences +10

A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver

Hiromi Yamashita, Makoto Takenoshita, Masaharu Sakurai et al. · Proceedings of the National Academy of Sciences · 2001 · 667 citations · Full text

A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism

Mark A. Herman, Odile D. Peroni, Jorge Villoria et al. · Nature · 2012 · 592 citations

Obesity, Metabolic Syndrome, Molecular Physiology +14

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Arun J. Sanyal, Edgar D. Charles, Brent A. Neuschwander‐Tetri et al. · The Lancet · 2018 · 511 citations

Inflammation, Hepatology, Medicine +7